SICOR Announces Approval of G-CSF in Lithuania
SICOR Inc. announced that its wholly owned subsidiary, SICOR Biotech UAB, has received final regulatory approval from the State Medicines Control Agency at the Ministry of Health in the Republic of Lithuania for the manufacture and marketing of recombinant human granulocyte colony stimulating factor, (r-metHuG-CSF or filgrastim) in Lithuania under the trade name, Grasalva(TM). SICOR Biotech plans to launch this product in Lithuania during the fourth quarter of 2003.
"This approval will provide greater access to a product with a proven track record of clinical success at an affordable cost to patients and health payers in Lithuania," stated Marvin Samson, president and chief executive officer. "This latest approval also provides an important addition to our growing biotechnology portfolio in Eastern Europe and demonstrates our commitment to bringing these important products to market in Eastern Europe and eventually, around the world."
Filgrastim is used to stimulate the growth of white blood cells that help to fight infections. The administration of filgrastim may reduce the duration of neutropenia (low white blood cell counts). The branded product, NEUPOGEN(R), is marketed by Amgen Inc.
Other news from the department business & finance
